

The information in the press release is intended for investors.

Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on January 4, 2024

Today on January 4, 2024 in Gothenburg, Sweden – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its extraordinary general meeting (“EGM”) at which the following principal resolutions were passed.

Election of members and chairman of the board, determination of fees to the board of directors

The EGM resolved that the number of members of the board of directors shall be five without deputies.

The EGM resolved that the board of directors shall consist of Jan-Eric Österlund, Lars Lind, Sten Nilsson, Helena Taflin and Alain Herrera with Jan-Eric Österlund as chairman. All elections for the period until the end of the next annual general meeting.

The EGM resolved that fees to the new members and the new chairman of the board of directors shall be paid in accordance with the remuneration levels resolved by the annual general meeting 2023, proportionate to the length of the term of office.

For more information, please contact

Isofol Medical AB (publ)

Jan-Eric Österlund, chairman of the board

E-mail: jan-eric@osterlund.co.uk

Phone: +44 7785 368 155

Roger Tell, acting CEO

E-mail: roger.tell@isofolmedical.com

Phone: +46 (0) 760 29 39 11

The information was submitted for publication, through the agency of the contact persons set out above, at 16:40 CET on January 4, 2024.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofolmedical.com